Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
Not Confirmed
Not Confirmed
27-30 April, 2026
Not Confirmed
Not Confirmed
27-30 April, 2026
Bioprocess Internation...Bioprocess International Europe
Not Confirmed
Not Confirmed
27-30 April, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS





Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
27-30 April, 2026
Industry Trade Show
Not Confirmed
27-30 April, 2026
Bioprocess Internation...Bioprocess International Europe
Industry Trade Show
Not Confirmed
27-30 April, 2026
Digital content

19 Feb 2026
// PHARMIWEB
https://www.pharmiweb.com/press-release/2026-02-19/brenus-pharma-presented-new-preclinical-and-early-clinical-data-in-colorectal-cancer-during-aacr-imm

06 Jan 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260106391108/en/Brenus-Pharma-Reports-Favorable-Tolerability-and-Clinical-Signals-in-Early-Preliminary-Results-of-First-In-Human-Study-for-STC-1010-in-Unresectable-Metastatic-Stage-Colorectal-Cancer-MSS-CRC-Patients

12 Nov 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251112049028/en/Brenus-Pharma-Expands-Its-Global-Scientific-Advisory-Board-With-Us-Immuno-Oncology-Expert-Prof.-Olivera-J.-Finn

02 Sep 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250901588403/en/Brenus-Pharma-Announces-First-Patients-Dosed-in-its-First-in-Human-Trial-Evaluating-STC-1010-a-Next-Generation-Immunotherapy

19 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250618487695/en/Brenus-Pharma-and-InSphero-Have-Developed-3D-Tumor-Spheroids-Mimicking-in-vivo-Human-Colorectal-Cancer-Conditions-and-Confirming-STC-1010s-Efficacy

07 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250507231535/en/AACR-2025-Brenus-Pharma-Presents-Late-breaking-Preclinical-Data-on-its-off-the-shelf-Next-generation-Vaccine-based-Immunotherapy-Candidate-STC-1010-Now-Moving-to-Clinic
ABOUT THIS PAGE